South & Central America Upstream Bioprocessing Market Forecast to 2030 - Regional Analysis by Product Type, Workflow, Usage Type, and Mode

The South & Central America upstream bioprocessing market was valued at US$ 382.56 million in 2022 and is expected to reach US$ 981.89 million by 2030; it is estimated to grow at a CAGR of 12.5% from 2022 to 2030.

Technological Advancements Fuel South & Central America Upstream Bioprocessing Market.

The upstream bioprocessing market is experiencing a wave of technological advancements, presenting considerable industry opportunities. These advancements include innovative developments in cell culture systems, bioreactor design, process monitoring, and control, as well as the integration of automation and digitalization. In September 2023, Repligen Corporation and Sartorius introduced an integrated bioreactor system. Repligen's XCell Alternating Tangential Flow (ATF) upstream intensification technology has been integrated into the Sartorius Biostat stirred-tank reactor (STR). This bioreactor technology is designed to make the application of N perfusion and intensified seed train easier for biopharmaceutical firms.

An embedded XCell ATF hardware and software module that combines integrated process analytical technologies with predefined advanced control recipes is incorporated into Biostat STR. This module is intended to simplify the management of cell growth and enhance cell retention in perfusion procedures, eliminating the need for a separate cell retention control tower. Such modern products feature enhanced process efficiency, scalability, and adaptability, which are crucial for meeting the evolving demands of biopharmaceutical production.

Advanced cell culture media formulations and next-generation bioreactor technologies are contributing to the optimization of upstream bioprocessing, in turn, enabling higher product yields, improved product quality, and the efficient production of complex biologics. The ongoing integration of advanced analytics and real-time process monitoring is revolutionizing data-driven decision-making in bioprocessing, driving precision and process optimization opportunities. Progress in biotechnology also fosters the development of flexible and modular manufacturing platforms.

Additionally, the convergence of machine learning, artificial intelligence, and predictive analytics is paving the way for predictive bioprocessing, thereby unlocking proactive process control, quality assurance, and cost optimization opportunities. Thus, technological advancements in upstream bioprocessing are reshaping the industry, presenting new avenues for innovation, efficiency, and adaptability.

South & Central America Upstream Bioprocessing Market Overview

The South & Central America upstream bioprocessing market is segmented into Brazil, Argentina, and the Rest of South & Central America. Recent technological advancements have had a direct impact on the economy of Brazil. Cost savings and higher work efficiencies achieved are cited as the major points attracting manufacturing companies to establish bases in South America.

South & Central America Upstream Bioprocessing Market Segmentation

• The South & Central America upstream bioprocessing market is segmented based on product type, workflow, usage type, mode, and country. Based on product type, the South & Central America upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The cell culture services held the largest market share in 2022.
• Based on workflow, the South & Central America upstream bioprocessing market is categorized into media preparation, cell culture, and cell separation. The cell separation held the largest market share in 2022.
• Based on usage type, the South & Central America upstream bioprocessing market is bifurcated into single-use and multi-use. The single-use held a larger market share in 2022
• Based on mode, the South & Central America upstream bioprocessing market is bifurcated into in-house and outsourced. The outsourced held a larger market share in 2022.
• Based on country, the South & Central America upstream bioprocessing market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America upstream bioprocessing market share in 2022.
• Thermo Fisher Scientific Inc, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, and Corning Inc are some of the leading companies operating in the South & Central America upstream bioprocessing market.

Market Highlights

• Based on product type, the South & Central America upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters segment held 35.2% market share in 2022, amassing US$ 134.60 million. It is projected to garner US$ 342.96 million by 2030 to expand at 12.4% CAGR during 2022-2030.
• The cell separation segment held 41.9% share of South & Central America upstream bioprocessing market in 2022, amassing US$ 160.27 million. It is projected to garner US$ 426.49 million by 2030 to expand at 13.0% CAGR during 2022-2030.
• The single-use segment held 54.3% share of South & Central America upstream bioprocessing market in 2022, amassing US$ 207.54 million. It is projected to garner US$ 542.00 million by 2030 to expand at 12.7% CAGR during 2022-2030.
• In terms of mode, the South & Central America upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house segment held 62.5% share of South & Central America upstream bioprocessing market in 2022, amassing US$ 239.23 million. It is projected to garner US$ 603.04 million by 2030 to expand at 12.3% CAGR during 2022-2030.
• This analysis states that Brazil captured 65.3% share of South & Central America upstream bioprocessing market in 2022. It was assessed at US$ 249.89 million in 2022 and is likely to hit US$ 654.80 million by 2030, exhibiting a CAGR of 12.8% during 2022-2030.
• In December 2023, Merck has acquired Erbi Biosystems, a Massachusetts-based company that developed the "Breez" 2 ml micro-bioreactor platform technology. Merck's upstream therapeutic protein portfolio is boosted by the purchase, enabling it to promptly develop lab-scale protocols for scalable cell-based perfusion bioreactor processes with capacities ranging from 2 ml to 2000 l. Additionally, it offers opportunities for further study and advancement in cutting-edge modality applications, like cell therapies. In May 2023, Danaher Corp announced that it has merged its Pall portfolio under the Cytiva brand. The merger has enhanced customers' access to bioprocess technologies and services. The merger will help the company offer biomanufacturers products and technologies across the full bioprocess spectrum, ranging from cell culture to drug products. All the products will be sold under the brand Cytiva. In addition, the merger has combined iCELLis, Kleenpak, Allegro, Supor, and Pegasus, in addition to ÄKTA, Amersham, B Sefia, Whatman, Xcellerex, Xuri, Biacore, FlexFactory, HyClone, and MabSelect.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America upstream bioprocessing market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in South & Central America upstream bioprocessing market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.